Promotional price valid on web orders only. Your contract pricing may differ. Interested in signing up for a dedicated account number?
Learn More
Learn More
Description
RECTAS (rectifier of aberrant splicing) is a pre-mRNA splicing modulator of the IKBKAP (inhibitor of Īŗ light polypeptide gene enhancer in B-cells, kinase complex associated protein) gene. It corrects aberrant IKBKAP splicing in vitro in cellular models of familial dysautonomia and in vivo in transgenic mice. In combination with Phenylbutyric acid (Cat. No. 2682), RECTAS rescues PARK7 aberrant splicing and neuronal cell loss in a midbrain organoid model of familial Parkinson's disease. Orally bioavailable and brain penetrant.
Greener Choice Claims
- Environmental benefits include:
- Ozone-Safe or Safe for the Ozone Layer
Specifications
Specifications
Chemical Name or Material | 2-Chloro-N-(2-furanylmethyl)-7 H-purin-6-amine |
CAS | 101862-47-9 |
Quantity | 50 mg |
Target | DNA, RNA and Protein Synthesis Compounds |
Molecular Formula | C10H8ClN5O |
Purity | 0.98 |
Product Suggestions
Customers who viewed this item also viewed
Viewing 1-4 of
Product Content Correction
Your input is important to us. Please complete this form to provide feedback related to the content on this product.
Product Title
Tocris Bioscience⢠RECTAS >
Spot an opportunity for improvement?Share a Content Correction